Agenus Profit Margin 2006-2021 | AGEN
Current and historical gross margin, operating margin and net profit margin for Agenus (AGEN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Agenus net profit margin as of September 30, 2021 is 0.38%.
|Agenus Annual Profit Margins
|Agenus Quarterly Profit Margins
||Medical - Biomedical and Genetics
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.